In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials

Clostridioides difficile is an important nosocomial pathogen that causes approximately 500,000 cases of C. difficile infection (CDI) and 29,000 deaths annually in the United States. Antibiotic use is a major risk factor for CDI because broad-spectrum antimicrobials disrupt the indigenous gut microbi...

Descripción completa

Detalles Bibliográficos
Autores principales: Selle, Kurt, Fletcher, Joshua R., Tuson, Hannah, Schmitt, Daniel S., McMillan, Lana, Vridhambal, Gowrinarayani S., Rivera, Alissa J., Montgomery, Stephanie A., Fortier, Louis-Charles, Barrangou, Rodolphe, Theriot, Casey M., Ousterout, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064742/
https://www.ncbi.nlm.nih.gov/pubmed/32156803
http://dx.doi.org/10.1128/mBio.00019-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064742/
https://www.ncbi.nlm.nih.gov/pubmed/32156803
http://dx.doi.org/10.1128/mBio.00019-20

Ejemplares similares